A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice

There is an ongoing need to develop strategic combinations of therapeutic agents to prevent type 1 diabetes (T1D) or to preserve islet β-cell mass in new-onset disease. Although clinical trials using candidate therapeutics are commonly based on preclinical studies, concern is growing regarding the r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes
Main Authors: Gill, Ronald G., Pagni, Philippe P., Kupfer, Tinalyn, Wasserfall, Clive H., Deng, Songyan, Posgai, Amanda, Manenkova, Yulia, Bel Hani, Amira, Straub, Laura, Bernstein, Philip, Atkinson, Mark A., Herold, Kevan C., von Herrath, Matthias, Staeva, Teodora, Ehlers, Mario R., Nepom, Gerald T.
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2016
Assuntos:
Immunology and Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5860426/
https://ncbi.nlm.nih.gov/pubmed/26718498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db15-0492
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados